Yang S, Yuan ZJ, Zhu YH, et al. - Given the widespread use of cetuximab in the clinical treatment of head and neck squamous cell carcinoma (HNSCC), experts aspired to explore whether long non-coding RNA plasmacytoma variant translocation 1 (lncRNA PVT1) is associated with cetuximab resistance. The levels of genes and proteins were quantified using Western blot and qRT-PCR, respectively. The Cell Counting Kit-8, Terminal deoxynucleotidyl transferase dUTP nick end labeling, and flow cytometry assays were used to assess cell functions.The level of methylation was determined using methylation-specific PCR. PVT1 was found to be upregulated and was associated with a poor prognosis of HNSCC. PVT1 overexpression markedly promoted survival and weakened the cetuximab sensitivity of HNSCC cells, whereas miR-124-3p overexpression had the reverse effect. PVT1 reduced HNSCC cell sensitivity to cetuximab by enhancing methylation-mediated inhibition of miR-124-3p, which may provide new insight into HNSCC cetuximab chemoresistance.